The Safety and Efficacy of OPC-64005 in the Treatment of Adult Attention-deficit/Hyperactivity Disorder

Adult Attention Deficit Hyperactivity Disorder Clinical Trial

Official title:
A Phase 2, Multicenter, Randomized, Double-blind, Active- and Placebo-controlled Trial of the Safety and Efficacy of OPC-64005 in the Treatment of Adult Attention-deficit/Hyperactivity Disorder

Status Completed

Clinical Trial Summary

A trial to assess the safety and efficacy of OPC-64005 in the treatment of adult attention-deficit/hyperactivity disorder.

Clinical Trial Description

A multicenter, randomized, double-blind, active- and placebo-controlled, parallel-design trial. ;

Study Design

Related Conditions & MeSH terms

Adult Attention Deficit Hyperactivity Disorder
Attention Deficit Disorder with Hyperactivity
Hyperkinesis

Clinical Trial Details

NCT number	NCT03324581
Study type	Interventional
Source	Otsuka Pharmaceutical Development & Commercialization, Inc.
Contact
Status	Completed
Phase	Phase 2
Start date	November 9, 2017
Completion date	October 31, 2018

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06000501` - Duration and Efficacy of Azstarys on Adult ADHD Symptoms and Executive Function in Early Evening	Phase 4
Completed	`NCT03721588` - Clinical and Suicidal Features of Urban, Turkish Middle Age Depressive Patients With Comorbid ADHD
Active, not recruiting	`NCT06221930` - Researching the Effectiveness of Attexis, a Digital Health Application for Adults With Attention Deficit Hyperactivity Disorder	N/A
Completed	`NCT02160262` - Open-label Safety Study in Adults With ADHD	Phase 3
Completed	`NCT02276209` - Dasotraline Adult ADHD Study	Phase 3
Completed	`NCT01692782` - Adult Attention Deficit Hyperactivity Disorder	Phase 2
Completed	`NCT01798381` - Essential Fatty Acids in Adult ADHD	Phase 3
Completed	`NCT00553319` - Study of Adderall-XR for the Treatment of Adult Attention Deficit Hyperactivity Disorder and Cocaine Dependence	Phase 2/Phase 3